Drug Update Quizz 1Created on April 16, 2023LuspaterceptLuspatercept is a first-in-class erythroid maturation agent (EMA) for use in the treatment of anemia in: - Adult patients with beta thalassemia ESA-naïve adult patients with very low- to intermediate-risk MDS Adult patients with very low- to intermediate-risk MDS after ESA failure All of the above Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation agent (EMA) for use in the treatment of anemia in patients with beta thalassemia and anemia in patients with myelodysplastic syndromes.Reblozyl is indicated for the treatment of:- Anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.- Anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.- Anemia failing an erythropoiesis stimulating agent and requiring 2 or more RBC units over 8 weeks in adult patients with very low- to intermediate risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). Change/Click on page numbers below for next Question Pages: 1 2 3 4 5 6 7 8
